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Abstract 
Background: The French Emergency Medicine Society, the French Intensive Care Society and the Pediatric Intensive 
Care and Emergency Medicine French‑Speaking Group edited guidelines on severe asthma exacerbation (SAE) in 
adult and pediatric patients.
Results: The guidelines were related to 5 areas: diagnosis, pharmacological treatment, oxygen therapy and ventila‑
tion, patients triage, specific considerations regarding pregnant women. The literature analysis and formulation of 
the guidelines were conducted according to the Grade of Recommendation Assessment, Development and Evalua‑
tion methodology. An extensive literature research was conducted based on publications indexed in PubMed™ and 
Cochrane™ databases. Of the 21 formalized guidelines, 4 had a high level of evidence (GRADE 1+/−) and 7 a low 
level of evidence (GRADE 2+/−). The GRADE method was inapplicable to 10 guidelines, which resulted in expert 
opinions. A strong agreement was reached for all guidelines.
Conclusion: The conjunct work of 36 experts from 3 scientific societies resulted in 21 formalized recommendations 
to help improving the emergency and intensive care management of adult and pediatric patients with SAE.
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Introduction
One of the most frequent chronic illnesses, asthma, 
affects 300 million people worldwide, 30 million of them 
in Europe [1]. The term “acute asthma attack” is com-
monly used by patients, but corresponds to no clinical 
entity and should no longer be used. Asthma exacerba-
tion is defined as an imbalance in the asthmatic disor-
der and is provoked acutely or subacutely by an external 
agent or by poor compliance with treatment [1]. Severe 
asthma exacerbation results from particularly severe 
bronchospasm and leads to severe obstructive syndrome. 
However, there is no consensual clinical definition of 
severe exacerbation [2, 3]. In these guidelines, we have 
chosen to define severe asthma exacerbation (SAE) as 
asthma exacerbation that is life-threatening or requires 
emergency management or both [4].
Aims of the guidelines
The most recent guidelines by the Société de réanimation 
de langue française (SRLF) for severe acute asthma in 
adults date from 2002. In view of therapeutic advances in 
noninvasive ventilation (NIV) and high-flow oxygen ther-
apy, recent international guidelines [1, 5, 6] and the need 
to optimize practices [7], it seemed necessary to summa-
rize current data. In this context, the Société française de 
médecine d’urgence (SFMU) and the SRLF propose these 
expert guidelines on the management of severe asthma 
exacerbation.
Method
These guidelines were drawn up by a group of experts 
convened by the SFMU and the SRLF. The group’s agenda 
was defined beforehand. The organizing committee first 
defined the questions to be addressed with the coordina-
tors and then designated the experts in charge of each 
question. The questions were formulated according to 
a Patient Intervention Comparison Outcome (PICO) 
format after a first meeting of the expert group. The lit-
erature was analyzed and the guidelines were formulated 
using Grade of Recommendation Assessment, Develop-
ment and Evaluation (GRADE) methodology. A level of 
proof was defined for each bibliographic reference cited 
depending on the type of study and could be reassessed 
in light of the methodological quality of the study. An 
overall level of proof was determined for each endpoint, 
taking into account the level of proof of each biblio-
graphic reference, the between-study consistency of the 
results, the direct or indirect nature of the results, and 
cost analysis.
A high overall level of proof enabled formulation of a 
“strong” recommendation (should be done…GRADE 1+, 
should not be done…GRADE 1−). A moderate, low, or 
very low overall level of proof led to the drawing up of an 
“optional” recommendation (should probably be done…
GRADE 2+, should probably not be done…GRADE 2−). 
When the literature was inexistent or insufficient, the 
question could be the subject of a recommendation in the 
form of an expert opinion (the experts recommend…). 
(Table  1) The proposed recommendations were pre-
sented and discussed one by one. The aim was not nec-
essarily to reach a single and convergent opinion of the 
experts on all the proposals, but to define the points of 
agreement and the points of disagreement or uncertainty. 
Each expert then reviewed and rated each recommenda-
tion using a scale of 1 (complete disagreement) to 9 (com-
plete agreement). The collective rating was done using a 
GRADE grid. To approve a recommendation regarding a 
criterion, at least 50% of the experts had to be in agree-
ment and less than 20% in disagreement. For an agree-
ment to be strong, at least 70% of the experts had to be in 
agreement. In the absence of strong agreement, the rec-
ommendations were reformulated and rated again, with 
a view to reaching a consensus. Only expert opinions that 
elicited strong agreement were kept.
Areas of recommendations
Five areas were defined: diagnosis and elements of the 
diagnosis, pharmacological treatment, methods of oxygen 
therapy and ventilation, transfer of patients, specific con-
siderations regarding pregnant women. A bibliographic 
search was conducted using the MEDLINE database via 
PubMed and the Cochrane database. For inclusion in the 
analysis, the publications had to be written in English or 
French. The analysis focused on recent data according to 
Table 1 Evidence grading and recommendations formulation
Recommendations formulation according to GRADE
High level of evidence Strong recommendation «should be…» Grade 1+
Intermediate to low level of evidence Optional recommendation «should probably…» Grade 2+
No or insufficient available data Expert opinion «the experts recommend…» Expert opinion
Intermediate to low level of evidence Optional recommendation «should probably not…» Grade 2−
High level of evidence Strong recommendation «should not be…» Grade 1−
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an order of appraisal ranging from meta-analyses to ran-
domized trials to observational studies. A summary of 
the recommendations is presented in Table 2.
Results
First area: diagnosis and elements of the diagnosis
For patients with asthma exacerbation, what severity cri-
teria in medical history and at initial physical examina-
tion are associated with an increased risk of mortality 
and/or intensive care admission?
R1.1 adult—From first contact with patients with 
asthma exacerbation, the following severity criteria should 
be sought: history of hospital admission for asthma or 
need for mechanical ventilation, recent use of oral corti-
costeroids, considerable or increasing use of beta-2 adr-
energic agonists, age > 70 years, difficulty speaking, altered 
consciousness, shock, respiratory rate > 30 breaths/min, 
arguments in favor of an underlying pneumonia.
GRADE 1+, STRONG AGREEMENT
Rationale
Several studies have tried to identify factors predictive 
of severe exacerbation in asthma patients. A 2005 meta-
analysis [8] reported a significant association between 
the risk of death (fatal asthma) or the use of mechanical 
ventilation (near-fatal asthma) and the following factors: 
hospitalization for asthma exacerbation, in particular 
admission to intensive care in the previous 12-month 
period; history of exacerbation that prompted the use of 
mechanical ventilation; recent or ongoing treatment with 
oral corticosteroids; and considerable (≥ 1 salbutamol 
inhaler per month) or increasing use of beta-2 adrener-
gic agonists [9]. Lack of controller therapy with inhaled 
corticosteroids [8] and psychosocial factors [10, 11] seem 
to be associated with a higher risk of severe exacerba-
tion. Published findings are conflicting. There are no data 
specific to risk evaluation by medical call centers. The 
abovementioned factors, along with difficulty speaking, 
are easily identifiable when a patient calls for emergency 
medical assistance. They are essential to assessment of 
asthma exacerbation severity and assessment of the risk 
of unfavorable progression. This should condition not 
only the medical decision at the call center, but also pre-
hospital management and destination of patients transfer.
The criteria of clinical severity on admission of patients 
with SAE have mainly been investigated in observational 
studies [1]. The criteria of poor prognosis used in these 
studies were death or the need for mechanical ventila-
tion. In patients admitted to intensive care, advanced 
age, neurological disorders, and tachycardia were clinical 
features associated with a poor prognosis [12, 13]. Data 
concerning hospitalized patients were reported by a 2017 
Japanese publication [14]. Age (> 70 years), shock, altered 
consciousness, and infectious lung disease were associ-
ated with increased risk of death. Peak expiratory flow 
(PEF) measured at admission was seldomly studied, but 
was not associated with a poor prognosis [15, 16].
R1.1 pediatric—From first contact with children with 
asthma exacerbation, the following severity criteria 
should probably be sought: allergens polysensitization, 
insufficiently treated or poorly controlled asthma, history 
of hospitalization for asthma, exposure to passive smok-
ing, and hypoxemia at initial management.
GRADE 2+, STRONG AGREEMENT
Rationale
Only three prospective studies, all of them single-center, 
described the risk factors for death or admission to pedi-
atric intensive care in case of severe asthma exacerbation 
in children [17–19]. The risk factors most commonly 
found are sensitization to multiple allergens, notably 
food allergens [17], history of hospitalization, especially 
admission to intensive care, or insufficiently controlled 
asthma (frequent nocturnal symptoms, frequent use of 
short-acting beta-2 adrenergic agonists, of oral corticos-
teroids, or of pediatric emergency services). Exposure to 
passive smoking and marked hypoxemia at initial man-
agement (oxygen saturation < 91% in ambient air) were 
reported as factors predictive of admission to intensive 
care in, respectively, three retrospective case–control 
studies and one retrospective case–control study.
First area: diagnosis and elements of the diagnosis
Should additional examinations be performed in patients 
with SAE in an emergency situation?
R1.2 adult—In SAE, chest radiography and blood gas 
measurements (venous or arterial) should probably be done 
if there is a diagnostic doubt or non-response to treatment.
GRADE 2+, STRONG AGREEMENT
Rationale
A cohort study failed to show any value of routine chest 
radiography in patients with SAE [20]. However, several 
guidelines underline its value in eliminating differen-
tial diagnoses. Chest radiography is recommended for 
patients presenting with wheezing/dyspnea and meeting 
at least one of the following criteria: history of chronic 
obstructive pulmonary disease, heart disease or thoracic 
surgery, suspicion of pneumonitis, immunosuppressed 
state. Arterial blood gas measurement should only be 
considered for SAE or exacerbations that fail to respond 
to initial treatment [21]. Normocapnia and hypercapnia 
are severity criteria of SAE. Measurement of venous blood 
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Table 2 Summary of recommendations
R1.1 adult—From first contact with patients with asthma exacerbation, the following severity criteria should be sought: history of 
hospital admission for asthma or need for mechanical ventilation, recent use of oral corticosteroids, considerable or increasing use of 
beta‑2 adrenergic agonists, age > 70 years, difficulty speaking, altered consciousness, shock, respiratory rate > 30 breaths/min, argu‑
ments in favor of an underlying pneumonia
Grade 1+
R1.1 pediatric—From first contact with children with asthma exacerbation, the following severity criteria should probably be sought: 
allergens polysensitization, insufficiently treated or poorly controlled asthma, history of hospitalization for asthma, exposure to pas‑
sive smoking, and hypoxemia at initial management
Grade 2+
R1.2 adult—In SAE, chest radiography and blood gas measurements (venous or arterial) should probably be done if there is a diagnos‑
tic doubt or non‑response to treatment
Grade 2+
R1.2 pediatric—The experts suggest that additional examinations are not more effective at diagnosing SAE in children than physical 
examination alone
Expert opinion
R2.1—Beta‑2 adrenergic agonists should not be administered intravenously first line in adult or pediatric patients with SAE even in 
mechanically ventilated patients
Grade 1−
R2.2—Beta‑2 adrenergic agonists should probably be administered by continuous rather than discontinuous nebulization during the 
first hour in adult and pediatric patients with SAE
Grade 2+
R2.3—Inhaled anticholinergic drugs should be combined with beta‑2 adrenergic agonists in adult and pediatric patients with SAE Grade 1+
R2.4—The experts suggest administering a 0.5‑mg dose of ipratropium bromide every 8 h in adults and children over 6 years of age, 
and a 0.25‑mg dose every 8 h in children under 6 years of age
Expert opinion
R2.5 adult—Systemic corticosteroid therapy should be administered early intravenously or orally (1 mg/kg of methylprednisolone 
equivalent, maximum 80 mg per day) to all adult patients with SAE
Grade 1+
R2.5 pediatric—Systemic corticosteroid therapy should probably be administered early intravenously or orally (2 mg/kg of methyl‑
prednisolone equivalent, maximum 80 mg per day) to children with SAE
Grade 2+
R2.6 adult—Magnesium sulfate should probably not be administered routinely to adult patients with SAE Grade 2−
R2.6 pediatric—Intravenous magnesium sulfate (dose ≥ 20 mg/kg) should be administered routinely to pediatric patients with SAE Grade 1+
R2.7—Antibiotic therapy should probably not be administered routinely during SAE in adult and pediatric patients. Antibiotic therapy 
should probably be reserved for cases of suspected bacterial pneumonia, based on usual clinical, radiological, and laboratory signs
Grade 2−
R3.1—Oxygen therapy titrated to a pulse oxygen saturation of 94% to 98% should probably be administered to adult and pediatric 
patients with SAE
Grade 2+
R3.2 adult—The experts were unable to recommend the use of NIV in SAE. High‑flow nasal oxygen therapy has yet to be assessed in 
this setting
Expert opinion
R3.2 pediatric—The use of NIV in children with SAE should probably be considered when conventional treatments fail Grade 2−
R3.2 pediatric—The experts are unable to recommend the use of high‑flow nasal oxygen in children with SAE Expert opinion
R3.3—The experts suggest resorting to intubation in adult and pediatric SAE patients if well‑conducted medical treatment fails or if 
the inaugural clinical presentation is severe (altered consciousness, bradypnea). Intubation should be performed using the orotra‑
cheal route, after rapid sequence induction including ketamine in first line of hypnotic agent and succinylcholine or rocuronium, by 
an experienced physician
Expert opinion
R3.4—The experts suggest prevention of lung overdistension by reducing tidal volume, respiratory rate, and positive end‑expiratory 
pressure (PEEP), and by increasing inspiratory flow, in order to limit plateau pressure in mechanically ventilated adult and pediatric 
patients with SAE
Expert opinion
R3.5 adult—The experts suggest deep sedation—Richmond Agitation‑Sedation Scale (RASS) of − 4 to − 5—at the initial phase of 
invasive mechanical ventilation, as well as neuromuscular blockers in the most severely ill patients. Their modalities are not specific 
to SAE. The experts are not able to recommend continuous administration of ketamine or halogenated agents
Expert opinion
R3.5 pediatric—Ketamine and halogenated gas should probably not be used for the sedation of mechanically ventilated children with 
SAE
Grade 2−
R3.6—Helium should probably not be used as carrier gas in nebulizers in adult and pediatric patients with SAE Grade 2−
R3.7 adult—The experts suggest that aerosols of salbutamol should be administered to spontaneously breathing patients with SAE 
using a nebulizer. The experts are unable to recommend a particular method of aerosol administration for patients with SAE receiv‑
ing mechanical ventilation
Expert opinion
R3.7 pediatric—The experts suggest providing a sufficient flow of air or oxygen to ensure the nebulization of inhaled treatments in 
spontaneously breathing children with SAE. The experts suggest continuing nebulization using specific systems in children with SAE 
who are mechanically ventilated
Expert opinion
R3.8—In the absence of compelling data in adult and pediatric patients with SAE, the experts suggest discussing with an expert 
center the use of extracorporeal life support—venovenous ECMO or extracorporeal CO2 removal (ECCO2R)—in the case of respira‑
tory acidosis and/or severe hypoxemia refractory to optimal medical treatment and to well‑conducted mechanical ventilation
Expert opinion
R4.1 adult—The experts suggest that the decision to send patients with SAE home should be based on an assessment taking into 
account the patient’s characteristics, the frequency of exacerbations, the severity of the initial clinical presentation, the response to 
treatment, including the progression of PEF, and the patient’s ability to be managed at home (referral to the primary care physician)
Expert opinion
R4.1 pediatric—The experts are unable to establish pediatric guidelines regarding the decision to send home children admitted for 
SAE
Expert opinion
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PCO2 is easier and less painful than arterial sampling, and 
a PvCO2 value below 45 mmHg excludes arterial hyper-
capnia [22]. To date, lung ultrasound has not been evalu-
ated in the diagnosis and management of asthma.
R1.2 pediatric—The experts suggest that additional 
examinations are not more effective at diagnosing SAE in 
children than physical examination alone.
EXPERT OPINION
Rationale
There is no pediatric study that has assessed the value of 
additional examinations in improving the reliability of the 
diagnosis of acute asthma in children. A single prospec-
tive, descriptive, single-center study has evaluated the 
value of chest ultrasound in acute asthma in children and 
reports that certain ultrasound signs may be associated 
with unfavorable progression [23]. Only chest radiogra-
phy could be performed in case of clinical sign or medical 
history suggestive of an alternate diagnosis (no family his-
tory of asthma, fever, localized auscultatory abnormality).
Second area: pharmacological treatment
What are the methods of administration of beta-2 adren-
ergic agonists in patients with SAE?
R2.1—Beta-2 adrenergic agonists should not be admin-
istered intravenously first line in adult or pediatric patients 
with SAE even in mechanically ventilated patients.
GRADE 1−, STRONG AGREEMENT
R2.2—Beta-2 adrenergic agonists should probably be 
administered by continuous rather than discontinuous 
nebulization during the first hour in adult and pediatric 
patients with SAE.
GRADE 2+, STRONG AGREEMENT
Rationale
Numerous studies [20, 24, 25], including a Cochrane 
meta-analysis [26], have compared continuous and 
intermittent administrations of inhaled beta-2 adrenergic 
agonists. Although there are few studies of high meth-
odological quality, at identical doses, continuous admin-
istration was associated with a significant decrease in 
the number of hospitalizations, and with improvements 
in the ventilatory parameters forced expiratory volume 
in 1  s (FEV1) and PEF. The observed effect was greater 
in patients presenting with significant signs of respira-
tory airways obstruction [25]. This effect seems to be 
independent of the dose administered since a compara-
tive study of 7.5 vs 2.5 mg/h in continuous nebulization 
resulted in a comparable improvement [24]. There was 
no increase in side effects or poor tolerance with contin-
uous administration [26]. In adults, there is no proof of 
the advantage of using oxygen, compared with air, as the 
aerosol carrier gas in non-hypoxemic patients. The intra-
venous route offers no advantage over inhalation as it has 
been associated with more side effects [27].
There is no pediatric study that has rigorously com-
pared the efficacy of continuous and intermittent nebu-
lization of short-acting beta-2 adrenergic agonists in 
children with SAE. Several cohort studies have demon-
strated that there is no increase in adverse effects (tachy-
cardia, hypokalemia) with continuous versus intermittent 
nebulization [28, 29].
Second area: pharmacological treatment
Should anticholinergic drugs be added to inhaled beta-2 
adrenergic agonists in patients with SAE?
R2.3—Inhaled anticholinergic drugs should be com-
bined with beta-2 adrenergic agonists in adult and pedi-
atric patients with SAE.
GRADE 1+, STRONG AGREEMENT
R2.4—The experts suggest administering a 0.5-mg dose 
of ipratropium bromide every 8 h in adults and children 
over 6 years of age, and a 0.25-mg dose every 8 h in chil-
dren under 6 years of age.
EXPERT OPINIONS
Table 2 (continued)
R4.2 adult—The experts suggest that the discharge prescription for patients treated for SAE in the ER should at least include a short‑
acting beta‑2 adrenergic agonist, oral corticosteroid therapy for a short period, and inhaled corticosteroid therapy if it has not been 
prescribed before
Expert opinion
R4.2 pediatric—The experts are unable to draw up pediatric guidelines regarding the hospital discharge prescription of children 
admitted for SAE
Expert opinion
R4.3—The experts suggest that admission to intensive care of adult and pediatric patients with SAE should be discussed early, on a 
case by case basis, because there are no specific criteria on this subject
Expert opinion
R5.1—Pregnant women with SAE should probably be treated in the same way as the general population, by intensifying their control‑
ling therapy upon admission to the emergency room if necessary
Grade 2+
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Rationale
The question of the addition of anticholinergic agents to 
bronchodilators has been addressed in several studies 
[30–32] and meta-analyses, including Cochrane studies in 
adults [33] and children [34]. Compared with the admin-
istration of beta-2 adrenergic agonists alone, the anticho-
linergic/bronchodilator combination increased FEV1 and 
PEF. A significant decrease of about 30% in hospitalizations 
was observed. It nonetheless seemed that the benefit of 
anticholinergics was greater in patients with the lowest PEF 
on admission. Their use is, therefore, less recommended 
in patients with non-severe asthma exacerbation. The use 
of repeated doses of anticholinergic drugs during initial 
management of SAE patients has not been shown to be 
beneficial. There was an overall increase in adverse effects 
frequency (dry mouth, tremor, nausea, headache, agitation) 
with combination therapy compared with beta-2 adrenergic 
agonists alone [32], without modification of the benefit–risk 
ratio. Despite a lack of data, the effect of anticholinergics in 
SAE seems to be unrelated to dose [35] and a single admin-
istration in the acute phase does not seem less effective clin-
ically than a dose repeated every 60 min [33]. The experts 
propose a dosage regimen of 0.5 mg of ipratropium bromide 
every 8 h for adults and children over 6 years of age and of 
0.25 mg every 8 h for children under 6 years of age.
Second area: pharmacological treatment
What are the methods of administration of corticosteroid 
therapy in patients with SAE?
R2.5 adult—Systemic corticosteroid therapy should 
be administered early intravenously or orally (1  mg/kg 
of methylprednisolone equivalent, maximum 80 mg per 
day) to all adult patients with SAE.
GRADE 1+, STRONG AGREEMENT
Rationale
A meta-analysis has shown that it is important to administer 
corticosteroids early, during the first hour of management of 
patients with SAE [36]. There is no evidence that the intra-
venous route is superior to the oral route (unless the latter is 
contraindicated) [36]. Inhalation has not proven better than 
the intravenous and oral routes and does not seem to be 
necessary as an adjunct to these two routes [37]. High doses 
of corticosteroids have not proven superior to low doses. 
A dose not exceeding 80 mg/day of methylprednisolone or 
400 mg of hydrocortisone, therefore, seems sufficient [38].
R2.5 pediatric—Systemic corticosteroid therapy should 
probably be administered early intravenously or orally 
(2  mg/kg of methylprednisolone equivalent, maximum 
80 mg per day) to children with SAE.
GRADE 2+, STRONG AGREEMENT
Rationale
A single randomized, controlled, double-blind pediatric 
study [39] comparing the use of systemic corticoster-
oid therapy with inhaled corticosteroid therapy in SAE 
showed that systemic corticosteroid therapy was more 
effective in terms of respiratory parameters improve-
ment. Other prospective studies [40–42] have yielded 
more heterogeneous results, given that they were con-
ducted in smaller study populations or did not specify 
the severity of asthma exacerbations [43].
Second area: pharmacological treatment
Is magnesium sulfate indicated in patients with SAE?
R2.6 adult—Magnesium sulfate should probably not be 
administered routinely to adult patients with SAE.
GRADE 2−, STRONG AGREEMENT
Rationale
Intravenous or inhaled magnesium sulfate has been pro-
posed as an adjuvant treatment of SAE because of its 
interesting experimental properties. However, there is 
no formal proof of its clinical efficiency. Several studies 
of low to modest level of proof have yielded discordant 
results. A well-conducted randomized, controlled study 
(3-Mg study) [44] showed no difference between asthma 
patients treated with magnesium sulfate or not regarding 
the need for hospital admissions, admissions to inten-
sive care, the length of hospitalization, mortality, or the 
progression of dyspnea or PEF. Benign side effects were 
significantly more frequent in the magnesium group. It 
should nonetheless be pointed out that some studies sug-
gest that magnesium sulfate is more effective in the most 
severely ill patients [15, 45–48], and that there is a cer-
tain heterogeneity in the studies regarding the disease 
severity of included patients. For example, the presence 
of clinical signs suggestive of a potentially life-threat-
ening condition was an exclusion criterion for the 3 Mg 
study and resulted in the exclusion of nearly 20% of the 
eligible patients. A meta-analysis [49] suggested a signifi-
cant reduction in admissions to intensive care in patients 
treated with magnesium sulfate, but the heterogeneity of 
the studies limited the significance of this conclusion. In 
contrast, the studies were in agreement that this treat-
ment had a relatively good safety profile and was not 
associated with severe side effects.
R2.6 pediatric—Intravenous magnesium sulfate 
(dose ≥ 20  mg/kg) should be administered routinely to 
pediatric patients with SAE.
GRADE 1+, STRONG AGREEMENT
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Rationale
A meta-analysis of five pediatric studies demonstrated, 
that in children with moderate to severe asthma exacer-
bation, magnesium sulfate improved respiratory param-
eters and reduced both the rate of hospitalization and 
the use of mechanical ventilation [50], which confirmed 
the findings of a previous randomized trial [51]. Studies 
have used different doses and methods of administration, 
but it seems that a dose equal to or greater than 20 mg/
kg is required. In contrast, nebulized magnesium sulfate 
seems to have no place in the treatment of asthma exac-
erbation in children [52].
Second area: pharmacological treatment
Should antibiotic therapy be administered to patients 
with SAE?
R2.7—Antibiotic therapy should probably not be 
administered routinely during SAE in adult and pediatric 
patients. Antibiotic therapy should probably be reserved 
for cases of suspected bacterial pneumonia, based on 
usual clinical, radiological, and laboratory signs.
GRADE 2−, STRONG AGREEMENT
Rationale
Respiratory infections are a frequent causal factor of 
SAE. Viruses play a major part, but bacterial infections 
may also be involved. Whereas the indication for anti-
biotic therapy is clear in the case of radiological opacity 
of the lung presumed to be of recent onset, its routine 
administration in SAE patients is debatable. In conclu-
sion, several arguments may not encourage the routine 
administration of penicillin or of macrolides to adults 
with SAE requiring hospitalization [53–56]. Several 
teams have studied the value of routine antibiotic treat-
ment in SAE requiring hospitalization. In adults, two 
randomized, controlled trials versus placebo assessed the 
benefits of routine administration of an oral macrolide 
for 3–10  days. The endpoint was the regression of res-
piratory symptoms at day 10. The first trial, which was 
positive, had several limitations regarding the antibiotic 
used (telithromycin) and a high rate (61%) of infection by 
intracellular bacteria in the population of the study [57]. 
The second trial, using azithromycin, was negative [58]. 
An older placebo-controlled trial showed no sympto-
matic benefit of antibiotic therapy with amoxicillin in an 
adult population [59]. A meta-analysis including trials in 
children and adults was also negative [60]. In conclusion, 
there is no argument encouraging the routine adminis-
tration of penicillin or of macrolides to adults with SAE 
requiring hospitalization. No study focused specifically 
on the most severely ill population, i.e., patients with SAE 
requiring admission to intensive care.
Third area: methods of oxygen therapy and ventilation
What are the methods of oxygen administration to 
patients with SAE?
R3.1—Oxygen therapy titrated to a pulse oxygen satu-
ration of 94%–98% should probably be administered to 
adult and pediatric patients with SAE.
GRADE 2+, STRONG AGREEMENT
Rationale
Although patients with SAE are often hypoxemic [61], 
few studies have evaluated the way of administration 
of oxygen therapy in these patients: fixed-flow oxygen 
using a facial mask or administration titrated to pulse 
oxygen saturation between 94 and 98%. The literature 
search revealed three studies with a low level of scientific 
proof (two randomized studies and one observational 
study) [62–64] that shared numerous biases: difficul-
ties in conducting a blinded study, small study popula-
tions, short-term evaluation (20–60 min) and, especially, 
no evaluation of “hard” outcomes (rates of intubation, 
intensive care admission, hospitalization, death). A sin-
gle study observed a deleterious effect of fixed-flow high-
concentration oxygen therapy on PEF [63]. In contrast, 
three studies were in agreement regarding the effect 
of fixed-flow high-concentration oxygen therapy on 
the increase in  PaCO2, compared with titrated oxygen 
therapy. This outcome alone does not allow a high level 
of recommendation in the absence of measured clinical 
impact, in contrast to data on other obstructive lung dis-
eases like chronic obstructive pulmonary disease.
Third area: methods of oxygen therapy and ventilation
Is there a role for non-invasive ventilation (NIV) or high-
flow oxygen therapy in patients with hypoxemic SAE?
R3.2 adult—The experts were unable to recommend the 
use of NIV in SAE. High-flow nasal oxygen therapy has 
yet to be assessed in this setting.
EXPERT OPINION
Rationale
NIV is increasingly used for the management of SAE 
[65, 66]. In several observational studies, NIV improved 
alveolar ventilation and successes were even reported 
in patients with disturbance of consciousness and with 
severe hypercapnia. A single study has shown a reduction 
in the rate of intubation with NIV [67]. However, the con-
clusions of this retrospective, single-center, before-after 
study cannot be generalized. In a large American database, 
the rate of intubation of patients treated by NIV was iden-
tical to that of the other patients [68]. Four randomized 
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controlled studies compared NIV with treatment without 
NIV [69–72]. All these studies reported clinical or spiro-
metric (decrease in respiratory rate, dyspnea, and signs 
of struggling to breathe, improvement in FEV1 or PEF) 
improvement. These effects were sometimes accompa-
nied by a reduction in the doses of salbutamol [70] and 
even in the risk of hospitalization and hospital stay. How-
ever, all these studies were in small numbers of patients 
(30–50). The authors of a systematic Cochrane review 
concluded that the data were insufficient to assess the 
effect of NIV on outcomes such as mortality, intubation, 
improvement in blood gases, and length of hospitalization 
[73]. In 2017, European and American societies were una-
ble to formulate a recommendation because of the uncer-
tainty and insufficiency of the data [74]. Although NIV 
seems to have beneficial clinical and spirometric effects, 
the experts are unable to recommend its use in SAE. No 
data are yet available regarding high-flow oxygen therapy.
R3.2 pediatric—The use of NIV in children with SAE 
should probably be considered when conventional treat-
ments fail.
GRADE 2+, STRONG AGREEMENT
R3.2 pediatric—The experts are unable to recommend 
the use of high-flow nasal oxygen in children with SAE.
EXPERT OPINION
Rationale
Three prospective studies, two of which were randomized 
and controlled [75, 76], found an improvement in clinical 
parameters and blood gas results when using NIV in SAE 
[77]. On the other hand, none of these studies showed any 
benefit in terms of length of hospital stay or the need for 
invasive ventilation. Data on the use of nasal humidified 
high-flow oxygen come solely from retrospective studies 
[78, 79], and so it is currently impossible to recommend 
its use in clinical practice in children with SAE.
Third area: methods of oxygen therapy and ventilation
What are the indications for and methods of intubation 
in patients with SAE?
R3.3—The experts suggest resorting to intubation in 
adult and pediatric SAE patients if well-conducted medi-
cal treatment fails or if the inaugural clinical presentation 
is severe (altered consciousness, bradypnea). Intubation 
should be performed using the orotracheal route, after 
rapid sequence induction including ketamine in first line 




Only 2% of patients hospitalized for SAE require intu-
bation [80]. The usual clinical criteria are the only deci-
sion-making arguments for intubation. Given associated 
high morbidity and mortality rates, intubation will only 
be considered as a last resort, in case of failure of well-
conducted medical treatment or when the clinical pres-
entation is severe at the onset of management (altered 
consciousness, bradypnea) [81]. It should be performed 
in accordance with the latest expert guidelines [82] and 
should be preceded by adequate pre-oxygenation and 
rapid sequence induction. It should be performed by the 
most experienced operator so as to reduce the risks of 
complications [83]. The orotracheal route is preferred. 
NIV cannot be established as the favored method of 
pre-oxygenation, but seems logical given the results 
obtained in other populations of patients. The use of 
ketamine or propofol as the main hypnotic agent dur-
ing rapid sequence induction can seem useful because 
of their theoretical bronchodilator effects [81]. However, 
no satisfactory scientific data formally validate their use 
in this indication. As in other indications for emergency 
intubation, it is justified to use a fast-acting neuromus-
cular blocker during anesthesia induction [82]. The sci-
entific data concerning the intubation of patients with 
SAE are extremely limited and come principally from 
general reviews and expert opinions, or from retrospec-
tive cohort studies that are generally single-center and 
include small numbers of patients. No randomized study, 
for example, is available regarding methods of intubation. 
We can, therefore, only formulate an expert opinion.
There is no pediatric study on the indications for intu-
bation in SAE, or on methods of intubation, and practices 
vary greatly [84]. The indications for intubation should be 
based on clinical judgment and it is probable that marked 
hypercapnia or hypoxia, or alterations of conscious-
ness are indications for invasive mechanical ventilation 
requirement. In addition, a cuffed tracheal tube of the 
largest possible diameter should probably be preferred.
Third area: methods of oxygen therapy and ventilation
What are the methods of invasive ventilation in intubated 
patients with SAE?
R3.4—The experts suggest prevention of lung overd-
istension by reducing tidal volume, respiratory rate, and 
positive end-expiratory pressure (PEEP), and by increas-
ing inspiratory flow, to limit plateau pressure in mechani-
cally ventilated adult and pediatric patients with SAE.
EXPERT OPINION
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Rationale
At the initial phase of management of SAE, lung overd-
istension by mechanical ventilation is deleterious as it is 
associated with a risk of barotrauma and induces arterial 
hypotension [85]. Minute ventilation [65] should be min-
imized by limiting tidal volume to 6–8 mL/kg [86, 87], o 
[86], and by increasing inspiratory flow to 60–80 L/min 
[88]. These goals are attained more easily in controlled 
volume mode, with constant inspiratory flow [85]. PEEP 
should be kept ≤ 5  cmH2O [89]. Maintenance of pla-
teau pressure < 30 cmH2O [13] is associated with a better 
prognosis. Monitoring of intrinsic PEEP has no benefits 
[86, 90]. All these settings are generally accompanied 
by often severe hypercapnia, which should be tolerated 
(except in the cases of cerebral edema, cranial trauma, 
and intracerebral mass). It is, therefore, legitimate to pre-
fer a heated humidifier to a heat and moisture exchanger. 
There are no literature data that allow recommendation 
of a given value of inspired oxygen fraction  (FiO2) or an 
oxygenation target.
No pediatric study has compared one ventilator mode 
to another for invasive mechanical ventilation in SAE.
Third area: methods of oxygen therapy and ventilation
What are the methods of sedation for mechanically ven-
tilated patients with SAE? Do halogenated anesthetics 
have a part to play?
R3.5 adult—The experts suggest deep sedation—Rich-
mond Agitation-Sedation Scale (RASS) of − 4 to − 5—at 
the initial phase of invasive mechanical ventilation, as 
well as neuromuscular blockers in the most severely ill 
patients. Their modalities are not specific to SAE. The 
experts are not able to recommend continuous adminis-
tration of ketamine or halogenated agents.
EXPERT OPINION
Rationale
Deep sedation (RASS between − 4 and − 5) is often nec-
essary at the initial phase of invasive ventilation given 
the marked activation of central respiratory drive by the 
conjunction of the respiratory condition itself, the large 
reduction in tidal volume, and hypercapnia. For the 
same reasons, it may be necessary to include continuous 
or transient neuromuscular block, in the most severely 
ill patients. Studies in these patients have reported an 
association between prolonged neuromuscular block-
ers by atracurium or vecuronium and neuromyopathy 
acquired in intensive care [91, 92]. This unwanted effect 
should be taken into account. Among available intrave-
nous sedatives, propofol has more marked bronchodi-
lator properties than benzodiazepines. Because of its 
own bronchodilator effect, continuously administered 
ketamine (1–2 mg/kg/h in the adult) in addition to con-
ventional sedation has been evaluated. Studies [93, 94] 
have reported benefits, at the cost of adverse effects 
(tachycardia, hallucination/confusion, hypersalivation) 
that are sometimes severe (myocardial infarction) [95]. 
Because of their bronchodilator properties, the benefits 
of halogenated agents (isoflurane and more recently sevo-
flurane) have been reported, especially in children [96]. 
An excellent understanding of the pharmacological prop-
erties, therapeutic modalities, and side effects of these 
agents is a necessary prerequisite to their administration.
R3.5 pediatric—Ketamine and halogenated gas should 
probably not be used for the sedation of mechanically 
ventilated children with SAE.
GRADE 2−, STRONG AGREEMENT
Rationale
A Cochrane meta-analysis [97] suggests that the use of 
ketamine in children with SAE provides no benefit. There 
is no other pediatric study on the use of “conventional” 
sedative agents in children with SAE. The literature on 
halogenated agents is essentially composed of retrospec-
tive studies in small populations and cannot be used to 
recommend their use in everyday practice [98, 99].
Third area: methods of oxygen therapy and ventilation
Does helium have a role as carrier gas for inhaled thera-
pies in patients with SAE?
R3.6—Helium should probably not be used as carrier 
gas in nebulizers in adult and pediatric patients with SAE.
GRADE 2−, STRONG AGREEMENT
Rationale
Helium is an inert monoatomic gas whose medical appli-
cations are linked to its physical properties and absence 
of side effects. Compared with an air–oxygen mixture, a 
helium–oxygen mixture has a lower density and higher 
viscosity, which improve the transition from turbulent to 
laminar flow, thus reducing the density-dependent com-
ponent of bronchial resistance. In SAE, a helium–oxygen 
mixture optimizes bronchial deposition of bronchodila-
tors. The literature contains 11 prospective randomized 
trials in adults [100–110] and a meta-analysis [111] com-
paring nebulization of beta-2 adrenergic agonists (most 
often albuterol) by a carrier gas composed of a helium–
oxygen mixture and a standard mixture of air–oxygen, in 
patients with SAE. No definitive conclusion can be drawn 
because these studies were very heterogeneous and 
included small populations.
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Third area: methods of oxygen therapy and ventilation
What are the methods of nebulization of therapeutic 
agents for patients with SAE?
R3.7 adult—The experts suggest that aerosols of salbu-
tamol should be administered to spontaneously breath-
ing patients with SAE using a nebulizer. The experts are 
unable to recommend a particular method of aerosol 




A meta-analysis showed equivalent efficacy for nebuliz-
ers and metered-dose inhalers coupled to valved hold-
ing chambers (spacers) [112]. However, in spontaneously 
breathing patients with SAE, the experts prefer the use 
of nebulizers, given their greater ease of use and because 
they do not require the cooperation of the patient [113]. 
The vast majority of studies have used air- or oxygen-
driven pneumatic nebulizers. Oxygen-driven jet nebu-
lization is preferable in the hypoxemic patient, but the 
expected FiO2 values are low because of the absence 
of an oxygen reservoir coupled to aerosol masks [114]. 
With their lower residual volume, ultrasonic nebulizers 
and vibrating mesh nebulizers have the same efficacy as 
pneumatic nebulizers and metered dose inhalers used 
with valved holding chambers [115]. In the absence of 
clinical evaluation in the setting of asthma, nebulization 
in a humidified nasal high-flow circuit cannot, at present, 
be recommended. Placing nebulizers within a high-flow 
nasal cannula oxygen therapy circuit is associated with a 
low amount of drug delivered in preclinical studies, and 
therefore does not seem advisable in the current state of 
knowledge at the time of guideline writing [116].
The recommendations regarding positive pressure 
respiratory assistance and high-flow oxygen therapy are 
only based on expert opinions, in vitro studies, and clini-
cal studies with a high risk of bias in very few subjects. 
There is no randomized study that has specifically com-
pared different aerosol generators in patients with SAE 
receiving mechanical ventilation. Ultrasonic nebulizers 
and vibrating mesh nebulizers and metered-dose inhal-
ers are effective in this context when they can be adapted 
to the ventilator. There is no reason to alter the ventila-
tor settings because of the administration of aerosols. It 
is essential to place a filter between the ventilator and 
the expiratory branch of the respiratory circuit, and to 
change it regularly [117].
R3.7 pediatric—The experts suggest providing a suffi-
cient flow of air or oxygen to ensure the nebulization of 
inhaled treatments in spontaneously breathing children 
with SAE. The experts suggest continuing nebulization 




There are no pediatric data on the methods of nebuliza-
tion in severe acute asthma in children.
Third area: methods of oxygen therapy and ventilation
What is the role of extracorporeal membrane oxygena-
tion (ECMO) in patients with SAE?
R3.8—In the absence of compelling data in adult and 
pediatric patients with SAE, the experts suggest dis-
cussing with an expert center the use of extracorporeal 
life support—venovenous ECMO or extracorporeal  CO2 
removal (ECCO2R)—in the case of respiratory acidosis 
and/or severe hypoxemia refractory to optimal medical 
treatment and to well-conducted mechanical ventilation.
EXPERT OPINION
Rationale
To date, the literature on the use of extracorporeal life 
support (ECMO or ECCO2R) in the management of 
SAE is extremely limited. The available data are from 
small retrospective cohorts [118–121]. Review of the 
International Extracorporeal Life Support Organiza-
tion Registry shows that ECMO was used in the setting 
of SAE in 24 of the 1257 patients included in the regis-
try. Hospital survival was 83%, compared with 51% in 
patients receiving venovenous ECMO for another cause 
[121]. As hypercapnia is prominent in refractory SAE, 
ECCO2R can be considered as a more accessible and 
less invasive technique than ECMO [118].
The use of extracorporeal life support in children 
with SAE has been described solely in clinical cases 
or in retrospective studies in small cohorts [120]. The 
survival rate in this indication seems good. The criteria 
for the use of extracorporeal life support have not been 
described in the literature.
Fourth area: transfer of patients
What are the criteria allowing hospital discharge of 
patients with SAE?
R4.1 adult—The experts suggest that the decision to 
send patients with SAE home should be based on an 
assessment taking into account the patient’s charac-
teristics, the frequency of exacerbations, the sever-
ity of the initial clinical presentation, the response to 
treatment, including the progression of PEF, and the 
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A return home can be envisaged when the symptoms 
improve after a few hours of treatment in the emer-
gency room. After an hour of continuous treatment 
with short-acting beta-2 adrenergic agonists, a return 
home can be envisaged for patients with improved 
symptoms, no further need for nebulized beta-2 adren-
ergic agonists, PEF that is 60%–80% of the patient’s the-
oretical maximum value, pulse oxygen saturation > 94% 
in ambient air, and a favorable home environment [1]. 
No study has validated factors predicting readmission 
of SAE patients.
R4.1 pediatric—The experts are unable to establish 
pediatric guidelines regarding the decision to send 
home children admitted for SAE.
EXPERT OPINION
Rationale
There are no pediatric data on the subject.
Fourth area: transfer of patients
For patients treated for SAE, what modalities of hospi-
tal discharge from the emergency room reduce the risk 
of a severe adverse event?
R4.2 adult—The experts suggest that the discharge 
prescription for patients treated for SAE in the ER 
should at least include a short-acting beta-2 adrenergic 
agonist, oral corticosteroid therapy for a short period, 




No study has specifically focused on the outcome of 
patients with SAE not hospitalized after an emergency 
room stay. On discharge, health professionals must 
inform the patient and ensure that he or she has a per-
sonalized plan of action [1]. A recent meta-analysis 
did not allow a conclusion to be drawn regarding the 
impact of these personalized action plans on mortal-
ity rate in adults [122]. In contrast, education of the 
patient reduced the rate of hospitalization in the weeks 
following the emergency room stay [123]. As for oral 
corticosteroid therapy, there are no consistent data on 
the length of treatment, the type of drug or the dose to 
be preferentially used [124]. A recent Cochrane meta-
analysis found no evidence for the additional value of 
inhaled corticosteroids, alone or combined with oral 
corticosteroid therapy, upon discharge from the emer-
gency room [37]. However, recent guidelines [1] recom-
mend initiation of inhaled corticosteroids in patients 
whose chronic treatment does not include them and 
the increase of their dosage for 2–4  weeks in patients 
already receiving inhaled corticosteroids. The discharge 
treatment should also include an inhaled short-acting 
beta-2 adrenergic agonist and a prescription for PEF 
device for home monitoring.
R4.2 pediatric—The experts are unable to draw up 
pediatric guidelines regarding the hospital discharge 
prescription of children admitted for SAE.
EXPERT OPINION
Rationale
There are no pediatric data on the subject.
Fourth area: transfer of patients
For patients with SAE, what criteria are used to indicate 
transfer from the emergency room to intensive care?
R4.3—The experts suggest that admission to intensive 
care of adult and pediatric patients with SAE should be 
discussed early, on a case-by-case basis, because there 
are no specific criteria on this subject.
EXPERT OPINION
Rationale
No randomized study or large-scale case–control study 
has conclusively confirmed the criteria justifying inten-
sive care unit admission of patients with SAE. However, 
epidemiological studies have identified the following epi-
demiological features correlated with admission to inten-
sive care [68, 125–127]: living in a disadvantaged area, 
psychiatric illness, substance abuse (heroin, cocaine), 
poor perception of dyspnea, history of admission to 
intensive care for SAE, history of intubation for SAE, 
repeated use of short-acting beta-2 adrenergic agonists, 
regular use of systemic corticosteroids. The clinical fea-
tures correlated with admission to intensive care were as 
follows: clinical signs of respiratory distress, PEF < 200 L/
min, improvement in PEF of < 10% after treatment, 
signs of acute cor pulmonale, poor hemodynamic toler-
ance, hypercapnia  (PaCO2 ≥ 45  mmHg) with or without 
acidemia, metabolic or mixed acidosis, abnormal chest 
radiography (barotrauma or lung disease). There are no 
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references concerning criteria for the hospitalization of 
children in continuous monitoring or intensive care pedi-
atric units. Age < 8 years, a history of admission to inten-
sive care for asthma, altered consciousness, and initial 
severity documented by a clinical score can be used to 
consider admission to intensive care or to a continuous 
monitoring unit [128, 129].
Fifth area: specificities of the pregnant woman
For pregnant women with SAE, does specific manage-
ment improve morbidity and mortality of mother and 
fetus compared with standard management?
R5.1—Pregnant women with SAE should probably be 
treated in the same way as the general population, by 
intensifying their controlling therapy upon admission to 
the emergency room if necessary.
GRADE 2+, STRONG AGREEMENT
Rationale
There is no study on specific management of SAE in 
pregnant women. Pregnant women with asthma exac-
erbation have been shown to receive fewer standard 
of care therapies in the emergency room [130]. Dur-
ing pregnancy, SAE is frequent and associated with 
an increased risk of maternal (pre-eclampsia, pre- and 
post-partum hemorrhage, prelabor rupture of mem-
branes, placental detachment, placenta previa) and fetal 
and neonatal (growth restriction, hypotrophy, prematu-
rity) complications [131–133]. During SAE, the benefits 
of treatments are much greater than the very low risk of 
malformation.
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